Synopsis: Astal Laboratories has initiated plans to raise up to ₹300 crore while scouting acquisitions of globally certified pharmaceutical plants, marking a dual-pronged strategy to accelerate entry into regulated export markets and strengthen manufacturing capabilities through inorganic expansion funded by institutional capital.
India’s pharmaceutical manufacturing sector is seeing strong demand from global drug companies seeking cost-efficient and regulatory-compliant production partners. Facilities with USFDA, EU-GMP, and WHO-GMP approvals command premium value due to access to regulated international markets.
For smaller pharma companies, acquiring an already-approved manufacturing plant is often faster and more efficient than building from scratch. New facilities require heavy capital investment, long approval timelines, and years of execution before generating revenue.
What’s the News?
At its board meeting held on June 29, 2026, Astal Laboratories Limited passed two consequential resolutions. First, it authorised Mr. Sudheer Karna Kankanala, Whole-time Director, to initiate discussions, evaluate opportunities, and negotiate the proposed acquisition of one or more pharmaceutical manufacturing units in India that carry USFDA and/or EU-GMP and/or WHO-GMP compliance or approval. The stated objective is to expand the company’s manufacturing capacity to meet rising order volumes and strengthen its presence in global markets.
The board also authorised CFO Mr. Balayogiswara Rao Peddinti to raise up to ₹300 crore through instruments including CCDs, CCPS, and NCDs via private placement, subject to shareholder and regulatory approvals.
Both resolutions are strategically connected, with the planned fundraising intended to finance these manufacturing acquisitions. This signals a coordinated expansion strategy where capital raising and capacity acquisition are being executed as part of a single long-term growth plan.
Following the latest market activity, shares of Astal Laboratories Ltd gained 1.78% in Monday afternoon trade, exchanging hands at ₹89.76. The pharmaceutical company currently commands a market capitalisation of approximately ₹378.93 crore and is trading at a trailing P/E ratio of 48.26.
The planned fundraise comes at a time when Astal Laboratories is already showing rapid operational expansion. According to its FY25 annual report, the company reported revenue growth of 171.64%, with revenue rising from ₹23.64 crore in FY24 to ₹64.23 crore in FY25, while profit after tax surged 1039.2% to ₹8.93 crore following its successful entry into the pharmaceutical bulk drug and intermediates business. This financial momentum suggests management is now attempting to scale aggressively through acquisitions rather than relying solely on organic capacity expansion.
Astal Laboratories appears to be accelerating its transition from a domestic bulk drug manufacturer into a globally focused pharmaceutical company. By pursuing acquisitions of already-approved manufacturing facilities instead of greenfield expansion, the company can significantly reduce regulatory timelines and execution risk. The move aligns with management’s broader long-term strategy of expanding global presence, strengthening API and intermediates manufacturing capabilities, and capitalizing on India’s growing pharmaceutical export opportunity
Company Overview
Incorporated in 1993 and formerly known as Macro International Limited, Astal Laboratories Limited has recently transformed itself into a pharmaceutical bulk drugs and intermediates manufacturer after altering its business model in 2023. The company currently operates a manufacturing facility at Raichur Industrial Estate in Karnataka and has established an early presence in pharmaceutical intermediates production, while management has indicated plans to begin API manufacturing as part of its next phase of growth.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
